Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors
✍ Scribed by Micaela Montanari; Alma Boninsegna; Beatrice Faraglia; Claudio Coco; Antonio Giordano; Achille Cittadini; Alessandro Sgambato
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 233 KB
- Volume
- 202
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Geminin is a potent inhibitor of origin assembly and re‐replication in multicellular eukaryotes and is a negative regulator of DNA replication during the cell cycle. Thus, it was proposed as an inhibitor of cell proliferation and as a potential tumor suppressor gene. However, the protein was found specifically expressed in proliferating lymphocytes and epithelial cells and up‐regulated in several malignancies. Therefore, geminin is now regarded as an oncogene but its role in tumor development remains unknown. In this study, we evaluated by Western blot analysis the expression of geminin in a series of human cancer cell lines of various histogenetic origin and in a series of human primary colon, rectal, and breast cancers. Expression of geminin was variable in different cell lines and not related to the expression level of the corresponding mRNA. Moreover, geminin was expressed at higher level in 56% and 58% of colon and rectal cancers, respectively, compared with the corresponding adjacent normal mucosa. A high expression of geminin was also detected by immunohistochemistry in 60% of human primary breast cancers. We also transfected a full‐length geminin cDNA in a human non‐tumorigenic and a cancer breast cell lines and obtained derivatives expressing high levels of the protein. Geminin overexpression stimulated cell cycle progression and proliferation in both normal and cancer cells and increased the anchorage—independent growth of breast cancer cells. These results demonstrate that expression of geminin is frequently deregulated in tumor cells and might play an important role in the regulation of cell growth in both normal and malignant cells. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The effects of EGF and TGF‐β1 on the proliferation of 2 ovarian carcinoma cell lines (IGROV1 and OVCCR1) were evaluated. The cell lines were adapted to grow in a restricted serum (0.5%) medium. EGF was required for proliferation of both ovarian cell lines. Low doses of TGF‐β1 inhibited
## Abstract The ErbB family of receptor kinases is composed of four members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Amplification of the ErbB2/neu is found in about 30% of breast cancer patients and is associated with a poor prognosis. Heregulin (HRG) activates
## Abstract Additive effects against tumor cells might be achieved by combining anti‐neoplastic agents directed against one or more altered mechanisms in cancer. We investigated the participation of gap junctional intercellular communication (GJIC), which is commonly dysfunctional in tumor cells as
## Abstract Membrane‐type metalloproteinase‐1 (MT1‐MMP) is a transmembrane metalloproteinase overexpressed in tumors, which plays a major role in the first step of pro‐MMP‐2 activation, leading to the generation of an intermediate 62 kDa species. The second step of MMP‐2 activation that yields to t
## Abstract “Loss of function” alterations in growth inhibitory signal transduction pathways are common in cancer cells. In this study, we show that growth arrest (GA) treatments—serum and growth factor withdrawal and growth inhibitory IL‐6 family cytokines (Interleukin‐6 and Oncostatin M (OSM))—in